Protocol Ledger

NCT06749899 · Phase III · RECRUITING

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Interventional Phase III clinical trial protocol NCT06749899 sponsored by Sun Yat-Sen University Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-04 Enrollment: 580 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06749899
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)580 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06749899
Protocol FieldVerified Registry Value
NCT IdentifierNCT06749899
Consolidated Lead SponsorSun Yat-Sen University Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment580 participants (ESTIMATED)
Registered Start Date2025-05-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06749899
Hospital Research SiteLocationSite Profile
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->
Dongguan People's HospitalDongguan, ChinaOpen Hospital Dossier ->
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->
Renmin Hospital of Wuhan UniversityWuhan, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI